Drugs · Entity Annotation Prototype (beta)

3articles mentioning drugs

4drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: Liposomal irinotecan ×

Liposomal irinotecan

This drug is selected. Its supporting articles are shown below.

Liposomal irinotecan3

Articles mentioning Liposomal irinotecan

3 articles · page 1 of 1

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study

bmjonc · full text · 2026-07-03 · 2 matching annotations

79.4%

Gem/NabP NALIRIFOX

…systemic palliative chemotherapy with NALIRIFOX, mFOLFIRINOX or Gem/NabP between January 2021 and July 2024. Key eligibility criteria re…

4CPS-013 Effectiveness and safety of liposomal irinotecan in the treatment of metastatic pancreatic cancer in routine clinical practice

ejhpharm · abstract · 2026-03-18 · 1 matching annotations

86.7%

gemcitabine-nabpaclitaxel liposomal irinotecan NALIRI fluorouracil folinic acid Metastatic pancreatic cancer NAPOLI-1 trial mPC

…nd lymph node (9%). In metastatic disease, 40 patients received gemcitabine-nabpaclitaxel as first-line treatment. Seventy-two percent of patients receiv…

Actionable mutations in pancreatic cancer: where targeted therapies are making a difference

bmjgast · abstract · 2025-11-27 · 1 matching annotations

86.3%

pembrolizumab 5-fluorouracil leucovorin adagrasib zenocutuzumab liposomal irinotecan daraxonrasib Pancreatic ductal adenocarcinoma (PDAC)NAPOLI-1 trial conventional chemotherapy

…d over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/…